Journal of Clinical Lipidology
Volume 2, Issue 6 , Pages 453-463 , December 2008

Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases

  • Eileen E. Ming, MPH, ScD

      Affiliations

    • AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, DE 19850 USA
    • University of Pennsylvania School of Medicine, Philadelphia, PA USA
    • Corresponding Author InformationCorresponding author
    • ,
  • Michael H. Davidson, MD

      Affiliations

    • University of Chicago Pritzker School of Medicine, Chicago, IL USA
    • ,
  • Sanjay K. Gandhi, PhD

      Affiliations

    • AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, DE 19850 USA
    • ,
  • Marcelo Marotti, MD, PhD

      Affiliations

    • AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom
    • ,
  • Carolyn G. Miles, MPH

      Affiliations

    • AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, DE 19850 USA
    • ,
  • Xiongkan Ke, MS

      Affiliations

    • AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, DE 19850 USA
    • ,
  • James M. McKenney, PharmD

      Affiliations

    • National Clinical Research, Richmond, VA USA

Received 10 October 2008 ,Accepted 19 October 2008.

References 

  1. Mackay J, Mensah GA. The atlas of heart disease and stroke. Geneva, Switzerland: WHO; 2004;
  2. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels (The Framingham Study). JAMA. 1986;256:2835–2838
  3. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? (Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)). JAMA. 1986;256:2823–2828
  4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  5. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003;24:1601–1610
  6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7–22
  7. Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS Investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696
  8. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278
  9. LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435
  10. Egger SS, Rätz Bravo AE, Hess L, Schlienger RG, Krähenbühl S. Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging. 2007;24:429–440
  11. Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol. 2006;97(suppl):27C–31C
  12. Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf. 2006;5:145–156
  13. Leape LL, Bates DW, Cullen DJ, et al. Systems analysis of adverse drug events (ADE Prevention Study Group). JAMA. 1995;274:35–43
  14. Heerey A, Barry M, Ryan M, Kelly A. The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci. 2000;169:176–179
  15. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36:1331–1336
  16. Etemad L. Statins and potentially interacting medications: a managed care perspective (Preventive medicine in managed care—statin drug interactions and implications for managed care). Am J Manag Care. 2004;4(suppl 2):S27–S29
  17. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacother. 1998;18:84–112
  18. Rosenson RS. Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther. 2003;1:495–505
  19. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother. 2001;35:1096–1107
  20. Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol. 2006;97(suppl):61C–68C
  21. US Food and Drug Administration. Information for healthcare professionals: simvastatin (marketed as Zocor and generics), ezetimibe/simvastatin (marketed as Vytorin), niacin extended-release/simvastatin(marketed as Simcor), used with amiodarone (Cordarone, Pacerone). Last updated August 8, 2008. http://www.fda.gov/cder/drug/InfoSheets/HCP/simvastatin_amiodaroneHCP.htmAccessed August 28, 2008
  22. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84:413–428
  23. Cooper KJ, Martin PD, Dane AL, et al. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol. 2003;55:94–99
  24. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol. 2004;94:1140–1146
  25. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80:565–581
  26. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292:2585–2590
  27. Andrade SE, Graham DJ, Staffa JA, et al. Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis. J Clin Epidemiol. 2005;58:171–174
  28. Flockhart Drug Interaction. Last updated July 24, 2008. http://www.medicine.iupui.edu/flockhart/table.htmAccessed August 13, 2008
  29. Worz CR, Bottorff M. The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins. Expert Opin Pharmacother. 2001;2:1119–1127
  30. Hamilton RA, Briceland LL, Andritz MH. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacotherapy. 1998;18:1112–1120
  31. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200–1205
  32. Chan M, Nicklason F, Vial JH. Adverse drug events as a cause of hospital admission in the elderly. Intern Med J. 2001;31:199–205
  33. Morera T, Gervasini G, Carrillo JA, Benitez J. Using a computerized drug prescription screening system to trace drug interactions in an outpatient setting. Ann Pharmacother. 2004;38:1301–1306
  34. Piacentini N, Trifiró G, Tari M, Moretti S, Arcoraci V UVEC Group. Statin-macrolide interaction risk: a population-based study throughout a general practice database. Eur J Clin Pharmacol. 2005;61:615–620
  35. Einarson TR, Metge CJ, Iskedjian M, Mukherjee J. An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a Canadian population-based study. Clin Ther. 2002;24:2126–2136
  36. Molden E, Skovlund E, Braathen P. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors. Drug Safety. 2008;31:587–596
  37. Flockhart Guidance for Industry. Drug interaction studies—study design, data analysis, and implications for dosing and labeling. September 2006. http://www.fda.gov/cder/guidance/6695dft.pdfAccessed August 13, 2008
  38. Davidson MH. Does differing metabolism by cytochrome P450 have clinical importance?. Curr Atheroscler Rep. 2000;2:14–19
  39. Grant RW, O'Leary KM, Weilburg JB, Singer DE, Meigs JB. Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med. 2004;164:2343–2348
  40. Mantel-Teeuwisse AK, Klungel OH, Schalekamp T, et al. Suboptimal choices and dosing of statins at start of therapy. Br J Clin Pharmacol. 2005;60:83–89

PII: S1933-2874(08)00893-3

doi: 10.1016/j.jacl.2008.10.007

Journal of Clinical Lipidology
Volume 2, Issue 6 , Pages 453-463 , December 2008

Article Tools

* Image Usage & Resolution